Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 7 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
VASCO PHARMA from Kontich, company number BE0870190760, closed financial year 2025 with a result of € 59,969 after tax. For that financial year VASCO PHARMA recorded a gross margin of € 175,494 and equity of € 877,633. Compared with financial year 2024, the result moved from € -8,846 to € 59,969. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 14, 2026.
€ 877,633
▲ 7% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 59,969
▲ still € 8,846 loss in 2024
Profit after tax over the fiscal year.
€ 20,293
▼ 80% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 833 paid out
1 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
Debts at end 2025
€ 960,001
▼ 8% vs 2024
€ 127,437 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.
€ 7,032
▼ 49% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 12,528
▼ 22% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 259,166 | € 256,660 | € 117,685 | € 175,494 | ▲ 49% |
| Profit after taxes | € 152,980 | € -166,845 | € -8,846 | € 59,969 | ▲ € 68,816 |
| Equity | € 994,188 | € 827,343 | € 818,497 | € 877,633 | ▲ 7% |
| Total debts | € 1,663,710 | € 1,497,047 | € 1,330,340 | € 1,138,841 | ▼ 14% |
| Cash | € 26,914 | € 25,384 | € 102,066 | € 20,293 | ▼ 80% |
| Land & buildings | € 1,294,206 | € 1,255,422 | € 1,193,402 | € 1,156,536 | ▼ 3% |
| Retained profit | € 698,742 | € 531,897 | € 523,051 | € 582,187 | ▲ 11% |
| Dividend | € 0 | € 0 | € 0 | € 833 | |
| Bank debt | € 1,266,310 | € 1,168,933 | € 1,043,603 | € 960,001 | ▼ 8% |
| Balance sheet total | € 2,725,231 | € 2,387,515 | € 2,207,753 | € 2,071,182 | ▼ 6% |
Key figures of VASCO PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to VASCO PHARMA?
What happened at VASCO PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 59,969. Source: NBB ↗
- New establishment in Kontich. KBO
- Start of the company according to the CBE. KBO
In short
From € 152,980 profit in 2022 to € 59,969 profit in 2025.
Paid € 102,973 in corporate taxes since 2022.
Best year ever: 2022, with € 152,980 profit.
Paid out € 833 in dividends to the owners in total.
A new publication or filing at VASCO PHARMA? We notify you, reason included.
Follow VASCO PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind VASCO PHARMA is Marleen Nijs. It owns 100% of Apotheek De Reiger itself.
Directors
According to the 2025 annual accounts
Establishments
Establishment units
Physical locations of this company
Kontichhof 15
2550 Kontich
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0870.190.760
- VAT number
- BE 0870.190.760
- Registered office
- Kontichhof 15, 2550 Kontich
- Names & denominations
- VASCO PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 25 November 2004
- Peppol
- Active · Active since 17 Mar 2025
- Activities · NACE
Activiteiten van holdings
Managementactiviteiten van holdings
Holdings
Administratieve en ondersteunende activiteiten ten behoeve van kantoren
Overige activiteiten i .v.m. administratie, n.e.g.
Diverse administratieve activiteiten ten behoeve van kantoren